-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Eight percent of the migraine population suffers from chronic migraine (CM) , defined as 15 headache days per month, which includes ≥8 days/month with symptoms that meet the diagnostic criteria for migraine
Previous studies of CM with MO (CMMO) have provided evidence of the effectiveness of two patient-centered treatment strategies: migraine preventive medications that stop overuse and migraine preventive
We sought to determine whether migraine prophylaxis that did not switch or limit the frequency of overmedication was comparable to migraine prophylaxis that switched from overmedication to the use of alternative medications <2 days per week
- A random sample of 720 participants, with a mean age of 44 years (SD 13 years), was 87.
Using a reduction in the number of days with moderate to severe headaches as a consequence of CMMO treatment concerns, migraine prophylaxis without switching or limiting symptomatic medication was not inferior to migraine prophylaxis with switching to a different symptomatic medication (up to 2 days per week)Source: Schwedt T, Hentz J, Sahai-Srivastava S, et al.
Schwedt T, Hentz J, Sahai-Srivastava S, et al.
Patient-Centered Treatment of Chronic Migraine With Medication Overuse: A Prospective, Randomized, Pragmatic Clinical Trial [published online ahead of print, 2022 Feb 15].
Neurology.
2022;10.
1212 /WNL.
0000000000200117.
doi:10.
1212/WNL.
0000000000200117Leave
a message here